Smith & Nephew (LON:SN) was downgraded by equities researchers at Barclays to an "equal weight" rating in a report released on Wednesday, MarketBeat.com reports. They currently have a GBX 1,240 ($16.37) price target on the stock, up from their prior price target of GBX 1,230 ($16.24). Barclays PLC's target price would suggest a potential downside of 2.97% from the stock's current price.
Smith & Nephew opened at 1260.36 on Wednesday. Smith & Nephew has a 1-year low of GBX 1,006.20 and a 1-year high of GBX 1,324.00. The company's market capitalization is GBX 11.27 billion. The stock has a 50 day moving average price of GBX 1,257.95 and a 200-day moving average price of GBX 1,175.18.
A number of other research firms have also recently issued reports on SN. Berenberg Bank increased their target price on Smith & Nephew from GBX 1,300 ($17.17) to GBX 1,485 ($19.61) and gave the stock a "buy" rating in a report on Tuesday, July 12th. BNP Paribas reiterated an "outperform" rating and set a GBX 1,425 ($18.82) target price on shares of Smith & Nephew in a report on Tuesday, July 12th.
Credit Suisse increased their target price on Smith & Nephew from GBX 1,165 ($15.38) to GBX 1,325 ($17.50) and gave the stock a "neutral" rating in a report on Friday, July 8th. Jefferies Group reiterated a "buy" rating and set a GBX 1,420 ($18.75) target price on shares of Smith & Nephew in a report on Thursday, July 28th.
Finally, JPMorgan Chase & Co reiterated a "neutral" rating and set a GBX 1,196 ($15.79) target price on shares of Smith & Nephew in a report on Friday, July 15th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of "Hold" and a consensus price target of GBX 1,294.92 ($17.10).
Company
Smith & Nephew is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.